
May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 68% REDUCTION IN RISK OF DISEASE RECURRENCE OR DEATH
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 80% REDUCTION IN LOCOREGIONAL RECURRENCE RISK
REGENERON PHARMACEUTICALS INC - LIBTAYO SHOWS 65% REDUCTION IN DISTANT RECURRENCE RISK
REGENERON PHARMACEUTICALS INC - REGULATORY APPLICATIONS SUBMITTED IN U.S. AND EU FOR LIBTAYO